Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Evaluation of in vitro methods for testing tigecycline combinations against carbapenemase-producing K.pneumoniae isolates.

Papoutsaki V, Galani I, Papadimitriou E, Karantani I, Karaiskos I, Giamarellou H.

J Glob Antimicrob Resist. 2019 Aug 6. pii: S2213-7165(19)30194-8. doi: 10.1016/j.jgar.2019.07.028. [Epub ahead of print]

PMID:
31398495
2.

Multifaceted mechanisms of colistin resistance revealed by genomic analysis of multidrug-resistant Klebsiella pneumoniae isolates from individual patients before and after colistin treatment.

Zhu Y, Galani I, Karaiskos I, Lu J, Aye SM, Huang J, Yu HH, Velkov T, Giamarellou H, Li J.

J Infect. 2019 Oct;79(4):312-321. doi: 10.1016/j.jinf.2019.07.009. Epub 2019 Jul 30.

PMID:
31374222
3.

The "Old" and the "New" Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How.

Karaiskos I, Lagou S, Pontikis K, Rapti V, Poulakou G.

Front Public Health. 2019 Jun 11;7:151. doi: 10.3389/fpubh.2019.00151. eCollection 2019. Review.

4.

Correction to: In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016.

Galani I, Souli M, Nafplioti K, Adamou P, Karaiskos I, Giamarellou H, Antoniadou A; Study Collaborators.

Eur J Clin Microbiol Infect Dis. 2019 Jun;38(6):1151-1152. doi: 10.1007/s10096-019-03553-8.

PMID:
31037478
5.

Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.

Galani I, Antoniadou A, Karaiskos I, Kontopoulou K, Giamarellou H, Souli M.

Clin Microbiol Infect. 2019 Jun;25(6):763.e5-763.e8. doi: 10.1016/j.cmi.2019.03.011. Epub 2019 Mar 28.

PMID:
30928562
6.

Correction to: Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance.

Galani I, Nafplioti K, Adamou P, Karaiskos I, Giamarellou H, Souli M; Study Collaborators.

BMC Infect Dis. 2019 Mar 7;19(1):230. doi: 10.1186/s12879-019-3854-1.

7.

In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016.

Galani I, Souli M, Nafplioti K, Adamou P, Karaiskos I, Giamarellou H, Antoniadou A; Study Collaborators.

Eur J Clin Microbiol Infect Dis. 2019 Jun;38(6):1143-1150. doi: 10.1007/s10096-019-03517-y. Epub 2019 Mar 1. Erratum in: Eur J Clin Microbiol Infect Dis. 2019 Apr 29;:.

PMID:
30825054
8.

Oral fosfomycin for the treatment of chronic bacterial prostatitis.

Karaiskos I, Galani L, Sakka V, Gkoufa A, Sopilidis O, Chalikopoulos D, Alivizatos G, Giamarellou E.

J Antimicrob Chemother. 2019 May 1;74(5):1430-1437. doi: 10.1093/jac/dkz015.

9.

Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance.

Galani I, Nafplioti K, Adamou P, Karaiskos I, Giamarellou H, Souli M; Study Collaborators.

BMC Infect Dis. 2019 Feb 15;19(1):167. doi: 10.1186/s12879-019-3801-1. Erratum in: BMC Infect Dis. 2019 Mar 7;19(1):230.

10.
11.

Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.

Karaiskos I, Galani I, Souli M, Giamarellou H.

Expert Opin Drug Metab Toxicol. 2019 Feb;15(2):133-149. doi: 10.1080/17425255.2019.1563071. Epub 2019 Jan 10. Review.

PMID:
30626244
12.

Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016.

Galani I, Karaiskos I, Karantani I, Papoutsaki V, Maraki S, Papaioannou V, Kazila P, Tsorlini H, Charalampaki N, Toutouza M, Vagiakou H, Pappas K, Kyratsa A, Kontopoulou K, Legga O, Petinaki E, Papadogeorgaki H, Chinou E, Souli M, Giamarellou H, On Behalf Of The Study Collaborators.

Euro Surveill. 2018 Aug;23(31). doi: 10.2807/1560-7917.ES.2018.23.30.1700775. No abstract available.

13.

Evaluation of ComASP™ Colistin (formerly SensiTest™ Colistin), a commercial broth microdilution-based method to evaluate the colistin minimum inhibitory concentration for carbapenem-resistant Klebsiella pneumoniae isolates.

Galani I, Adamou P, Karaiskos I, Giamarellou H, Souli M.

J Glob Antimicrob Resist. 2018 Dec;15:123-126. doi: 10.1016/j.jgar.2018.07.006. Epub 2018 Jul 20.

PMID:
30036693
14.

Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β-lactamase-producing Enterobacteriaceae.

Russo A, Falcone M, Gutiérrez-Gutiérrez B, Calbo E, Almirante B, Viale PL, Oliver A, Ruiz-Garbajosa P, Gasch O, Gozalo M, Pitout J, Akova M, Peña C, Cisneros JM, Hernández-Torres A, Farcomeni A, Prim N, Origüen J, Bou G, Tacconelli E, Tumbarello M, Hamprecht A, Karaiskos I, de la Calle C, Pérez F, Schwaber MJ, Bermejo J, Lowman W, Hsueh PR, Mora-Rillo M, Rodriguez-Gomez J, Souli M, Bonomo RA, Paterson DL, Carmeli Y, Pascual A, Rodríguez-Baño J, Venditti M; REIPI/ESGBIS/INCREMENT investigators.

Int J Antimicrob Agents. 2018 Nov;52(5):577-585. doi: 10.1016/j.ijantimicag.2018.06.018. Epub 2018 Jun 30.

PMID:
29969692
15.

Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing Escherichia coli and ESBL-Producing Klebsiella pneumoniae.

Scheuerman O, Schechner V, Carmeli Y, Gutiérrez-Gutiérrez B, Calbo E, Almirante B, Viale PL, Oliver A, Ruiz-Garbajosa P, Gasch O, Gozalo M, Pitout J, Akova M, Peña C, Molina J, Hernández-Torres A, Venditti M, Prim N, Origüen J, Bou G, Tacconelli E, Tumbarello M, Hamprecht A, Karaiskos I, de la Calle C, Pérez F, Schwaber MJ, Bermejo J, Lowman W, Hsueh PR, Navarro-San Francisco C, Bonomo RA, Paterson DL, Pascual A, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT investigators.

Infect Control Hosp Epidemiol. 2018 Jun;39(6):660-667. doi: 10.1017/ice.2018.63. Epub 2018 Apr 5.

PMID:
29618394
16.

Multifactorial chromosomal variants regulate polymyxin resistance in extensively drug-resistant Klebsiella pneumoniae.

Pitt ME, Elliott AG, Cao MD, Ganesamoorthy D, Karaiskos I, Giamarellou H, Abboud CS, Blaskovich MAT, Cooper MA, Coin LJM.

Microb Genom. 2018 Mar;4(3). doi: 10.1099/mgen.0.000158. Epub 2018 Feb 12.

17.

Combination therapy for extensively-drug resistant gram-negative bacteria.

Karaiskos I, Antoniadou A, Giamarellou H.

Expert Rev Anti Infect Ther. 2017 Dec;15(12):1123-1140. doi: 10.1080/14787210.2017.1410434. Epub 2017 Dec 1. Review.

PMID:
29172792
18.

Management of KPC-producing Klebsiella pneumoniae infections.

Bassetti M, Giacobbe DR, Giamarellou H, Viscoli C, Daikos GL, Dimopoulos G, De Rosa FG, Giamarellos-Bourboulis EJ, Rossolini GM, Righi E, Karaiskos I, Tumbarello M, Nicolau DP, Viale PL, Poulakou G; Critically Ill Patients Study Group of the European Society of Clinical Microbiology and Infectious Disease (ESCMID); Hellenic Society of Chemotherapy (HSC) and Società Italiana di Terapia Antinfettiva (SITA).

Clin Microbiol Infect. 2018 Feb;24(2):133-144. doi: 10.1016/j.cmi.2017.08.030. Epub 2017 Sep 9. Review.

19.

Point-prevalence survey of healthcare facility-onset healthcare-associated Clostridium difficile infection in Greek hospitals outside the intensive care unit: The C. DEFINE study.

Skoutelis A, Pefanis A, Tsiodras S, Sipsas NV, Lelekis M, Lazanas MC, Gargalianos P, Dalekos GN, Roilides E, Samonis G, Maltezos E, Hatzigeorgiou D, Lada M, Metallidis S, Stoupis A, Chrysos G, Karnesis L, Symbardi S, Loupa CV, Giamarellou H, Kioumis I, Sambatakou H, Tsianos E, Kotsopoulou M, Georgopali A, Liakou K, Perlorentzou S, Levidiotou S, Giotsa-Toutouza M, Tsorlini-Christoforidou H, Karaiskos I, Kouppari G, Trikka-Graphakos E, Ntrivala MA, Themeli-Digalaki K, Pangalis A, Kachrimanidou M, Martsoukou M, Karapsias S, Panopoulou M, Maraki S, Orfanou A, Petinaki E, Orfanidou M, Baka V, Stylianakis A, Spiliopoulou I, Smilakou S, Zerva L, Vogiatzakis E, Belesiotou E, Gogos CA.

PLoS One. 2017 Aug 16;12(8):e0182799. doi: 10.1371/journal.pone.0182799. eCollection 2017.

20.

Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study.

Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Paño-Pardo JR, Venditti M, Tumbarello M, Daikos G, Cantón R, Doi Y, Tuon FF, Karaiskos I, Pérez-Nadales E, Schwaber MJ, Azap ÖK, Souli M, Roilides E, Pournaras S, Akova M, Pérez F, Bermejo J, Oliver A, Almela M, Lowman W, Almirante B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT Investigators.

Lancet Infect Dis. 2017 Jul;17(7):726-734. doi: 10.1016/S1473-3099(17)30228-1. Epub 2017 Apr 22.

PMID:
28442293
21.

Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae.

Souli M, Karaiskos I, Masgala A, Galani L, Barmpouti E, Giamarellou H.

Eur J Clin Microbiol Infect Dis. 2017 Jul;36(7):1305-1315. doi: 10.1007/s10096-017-2936-5. Epub 2017 Feb 16.

PMID:
28210888
22.

A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae.

Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Paño-Pardo JR, Venditti M, Tumbarello M, Daikos G, Pintado V, Doi Y, Tuon FF, Karaiskos I, Machuca I, Schwaber MJ, Azap ÖK, Souli M, Roilides E, Pournaras S, Akova M, Pérez F, Bermejo J, Oliver A, Almela M, Lowman W, Almirante B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J; Investigators from the REIPI/ESGBIS/INCREMENT Group.

Mayo Clin Proc. 2016 Oct;91(10):1362-1371. doi: 10.1016/j.mayocp.2016.06.024. Erratum in: Mayo Clin Proc. 2016 Dec;91(12 ):1843.

PMID:
27712635
23.

Colistin: still a lifesaver for the 21st century?

Karaiskos I, Souli M, Galani I, Giamarellou H.

Expert Opin Drug Metab Toxicol. 2017 Jan;13(1):59-71. Epub 2016 Sep 14. Review.

PMID:
27573251
24.

Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration.

Karaiskos I, Friberg LE, Galani L, Ioannidis K, Katsouda E, Athanassa Z, Paskalis H, Giamarellou H.

Int J Antimicrob Agents. 2016 Sep;48(3):337-41. doi: 10.1016/j.ijantimicag.2016.06.008. Epub 2016 Jul 18.

PMID:
27474468
25.

Nationwide surveillance of resistance rates of Staphylococcus aureus clinical isolates from Greek hospitals, 2012-2013.

Souli M, Karaiskos I, Galani L, Maraki S, Perivolioti E, Argyropoulou A, Charissiadou A, Zachariadou L, Tsiplakou S, Papaioannou V, Tsorlini H, Katsifa H, Baka V, Pantazi P, Paschali A, Kyratsa A, Trikka-Graphakos E, Giannopoulou P, Vogiatzakis E, Moraitou H, Papadogeorgaki H, Avgerinou H, Panagea T, Pantazatou A, Petinaki E, Stamatopoulou G, Toutouza M, Karatzoglou I, Kontopoulou K, Orfanidou M, Karantani I, Fytas P, Tzanetou K, Platsouka E, Kazila P, Chli A, Statiri N, Giamarellou H.

Infect Dis (Lond). 2016 Apr;48(4):287-292. doi: 10.3109/23744235.2015.1110858. Epub 2015 Dec 4.

PMID:
26635179
26.

Plazomicin: an investigational therapy for the treatment of urinary tract infections.

Karaiskos I, Souli M, Giamarellou H.

Expert Opin Investig Drugs. 2015;24(11):1501-11. doi: 10.1517/13543784.2015.1095180. Epub 2015 Sep 30. Review.

PMID:
26419762
27.

Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.

Karaiskos I, Friberg LE, Pontikis K, Ioannidis K, Tsagkari V, Galani L, Kostakou E, Baziaka F, Paskalis C, Koutsoukou A, Giamarellou H.

Antimicrob Agents Chemother. 2015 Dec;59(12):7240-8. doi: 10.1128/AAC.00554-15. Epub 2015 Sep 14.

28.

Population Pharmacokinetics of Fosfomycin in Critically Ill Patients.

Parker SL, Frantzeskaki F, Wallis SC, Diakaki C, Giamarellou H, Koulenti D, Karaiskos I, Lipman J, Dimopoulos G, Roberts JA.

Antimicrob Agents Chemother. 2015 Oct;59(10):6471-6. doi: 10.1128/AAC.01321-15. Epub 2015 Aug 3.

29.

High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections.

Routsi C, Kokkoris S, Douka E, Ekonomidou F, Karaiskos I, Giamarellou H.

Int J Antimicrob Agents. 2015 Jan;45(1):90-3. doi: 10.1016/j.ijantimicag.2014.07.014. Epub 2014 Aug 30. No abstract available.

PMID:
25241261
30.

Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.

Karaiskos I, Giamarellou H.

Expert Opin Pharmacother. 2014 Jul;15(10):1351-70. doi: 10.1517/14656566.2014.914172. Epub 2014 Apr 28. Review.

31.

Large vessel vasculitis in a patient with acute Q-fever: A case report.

Baziaka F, Karaiskos I, Galani L, Barmpouti E, Konstantinidis S, Kitas G, Giamarellou H.

IDCases. 2014 Jul 31;1(3):56-9. doi: 10.1016/j.idcr.2014.07.004. eCollection 2014.

32.

Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.

Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, Oikonomou A, Poulakou G, Roilides E, Giamarellou H.

Int J Antimicrob Agents. 2014 Jan;43(1):52-9. doi: 10.1016/j.ijantimicag.2013.09.010. Epub 2013 Oct 16.

PMID:
24183799
33.

Nosocomial dissemination of Providencia stuartii isolates producing extended-spectrum β-lactamases VEB-1 and SHV-5, metallo-β-lactamase VIM-1, and RNA methylase RmtB.

Galani L, Galani I, Souli M, Karaiskos I, Katsouda E, Patrozou E, Baziaka F, Paskalis C, Giamarellou H.

J Glob Antimicrob Resist. 2013 Jun;1(2):115-116. doi: 10.1016/j.jgar.2013.03.006. Epub 2013 Apr 17. No abstract available.

PMID:
27873578
34.

Successful treatment of extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis with intraventricular colistin after application of a loading dose: a case series.

Karaiskos I, Galani L, Baziaka F, Katsouda E, Ioannidis I, Andreou A, Paskalis H, Giamarellou H.

Int J Antimicrob Agents. 2013 May;41(5):480-3. doi: 10.1016/j.ijantimicag.2013.02.010. Epub 2013 Apr 6.

PMID:
23566531
35.

Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review.

Karaiskos I, Galani L, Baziaka F, Giamarellou H.

Int J Antimicrob Agents. 2013 Jun;41(6):499-508. doi: 10.1016/j.ijantimicag.2013.02.006. Epub 2013 Mar 16. Review.

PMID:
23507414
36.

Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae.

Giamarellou H, Galani L, Baziaka F, Karaiskos I.

Antimicrob Agents Chemother. 2013 May;57(5):2388-90. doi: 10.1128/AAC.02399-12. Epub 2013 Feb 25.

37.

Correlation between Ki67 and breast cancer prognosis.

Kontzoglou K, Palla V, Karaolanis G, Karaiskos I, Alexiou I, Pateras I, Konstantoudakis K, Stamatakos M.

Oncology. 2013;84(4):219-25. doi: 10.1159/000346475. Epub 2013 Jan 24. Review.

PMID:
23364275
38.

Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration.

Karvanen M, Plachouras D, Friberg LE, Paramythiotou E, Papadomichelakis E, Karaiskos I, Tsangaris I, Armaganidis A, Cars O, Giamarellou H.

Antimicrob Agents Chemother. 2013 Jan;57(1):668-71. doi: 10.1128/AAC.00985-12. Epub 2012 Nov 12.

39.

Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill.

Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, Papadomichelakis E, Antoniadou A, Giamarellou H, Armaganidis A, Cars O, Friberg LE.

Antimicrob Agents Chemother. 2012 Aug;56(8):4241-9. doi: 10.1128/AAC.06426-11. Epub 2012 May 21.

40.

Gastrocolic fistulae; From Haller till nowadays.

Stamatakos M, Karaiskos I, Pateras I, Alexiou I, Stefanaki C, Kontzoglou K.

Int J Surg. 2012;10(3):129-33. doi: 10.1016/j.ijsu.2012.02.011. Epub 2012 Feb 20. Review.

41.

Cell cyclins: triggering elements of cancer or not?

Stamatakos M, Palla V, Karaiskos I, Xiromeritis K, Alexiou I, Pateras I, Kontzoglou K.

World J Surg Oncol. 2010 Dec 22;8:111. doi: 10.1186/1477-7819-8-111. Review.

42.

Early changes of procalcitonin may advise about prognosis and appropriateness of antimicrobial therapy in sepsis.

Georgopoulou AP, Savva A, Giamarellos-Bourboulis EJ, Georgitsi M, Raftogiannis M, Antonakos N, Apostolidou E, Carrer DP, Dimopoulos G, Economou A, Efthymiou G, Galanakis N, Galani L, Gargalianos P, Karaiskos I, Katsenos C, Kavatha D, Koratzanis E, Labropoulos P, Lada M, Nakos G, Paggalou E, Panoutsopoulos G, Paraschos M, Pavleas I, Pontikis K, Poulakou G, Prekates A, Sybardi S, Theodorakopoulou M, Trakatelli C, Tsiaoussis P, Gogos C, Giamarellou H, Armaganidis A, Meisner M; Hellenic Sepsis Study Group.

J Crit Care. 2011 Jun;26(3):331.e1-7. doi: 10.1016/j.jcrc.2010.07.012. Epub 2010 Sep 24.

PMID:
20869839
43.

Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.

Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H.

Antimicrob Agents Chemother. 2009 Aug;53(8):3430-6. doi: 10.1128/AAC.01361-08. Epub 2009 May 11.

44.

Severe dysphagia as the presenting symptom of Wernicke-Korsakoff syndrome in a non-alcoholic man.

Karaiskos I, Katsarolis I, Stefanis L.

Neurol Sci. 2008 Feb;29(1):45-6. doi: 10.1007/s10072-008-0859-8. Epub 2008 Apr 1.

PMID:
18379741

Supplemental Content

Loading ...
Support Center